Human 6-Sulfo LacNAc-Expressing Dendritic Cells Are Principal Producers of Early Interleukin-12 and Are Controlled by Erythrocytes

Immunity

Volumn 24, Issue 6, 2006, Pages 767-777

  Schäkel, Knut ^a,b   von Kietzell, Matthias ^a   Hänsel, Anja ^a   Ebling, Annette ^a   Schulze, Livia ^a   Haase, Michael ^b   Semmler, Christian ^b   Sarfati, Marika ^c   Barclay, A Neil ^d   Randolph, Gwendalyn J ^e   Meurer, Michael ^b   Rieber, E Peter ^a  

^a Helmholtz Zentrum Dresden Rossendorf   (Germany)

^b OncoRay   (Germany)

^c NOTRE DAME HOSPITAL   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CELLIMMUNO

Indexed keywords

CARBOHYDRATE DERIVATIVE; CD40 LIGAND; CD47 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 12P70; MONOCLONAL ANTIBODY; P SELECTIN GLYCOPROTEIN LIGAND 1; REGULATOR PROTEIN;

ARTICLE; CELL MATURATION; DENDRITIC CELL; ERYTHROCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; PRIORITY JOURNAL;

ANTIGENS, CD47; ANTIGENS, DIFFERENTIATION; ARTHRITIS, RHEUMATOID; CD40 LIGAND; COCULTURE TECHNIQUES; DENDRITIC CELLS; ERYTHROCYTES; HUMANS; INTERLEUKIN-12; LIGANDS; LIPOPOLYSACCHARIDES; MEMBRANE GLYCOPROTEINS; PSORIASIS; RECEPTORS, IMMUNOLOGIC; TH1 CELLS; TOLL-LIKE RECEPTOR 4;

EID: 33745062776     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2006.03.020     Document Type: Article

References (39)

1. Aoshiba K., Nakajima Y., Yasui S., Tamaoki J., and Nagai A. Red blood cells inhibit apoptosis of human neutrophils. Blood 93 (1999) 4006-4010
2. Arosa F.A., Pereira C.F., and Fonseca A.M. Red blood cells as modulators of T cell growth and survival. Curr. Pharm. Des. 10 (2004) 191-201
3. Brooke G., Holbrook J.D., Brown M.H., and Barclay A.N. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J. Immunol. 173 (2004) 2562-2570
4. Casey L.C., Balk R.A., and Bone R.C. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med. 119 (1993) 771-778
5. Chaudhari U., Romano P., Mulcahy L., Dooley L., Baker D., and Gottlieb A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
6. Cohen J. IL-12 deaths: explanation and a puzzle. Science 270 (1995) 908
7. de Baey A., Mende I., Baretton G., Greiner A., Hartl W.H., Baeuerle P.A., and Diepolder H.M. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J. Immunol. 170 (2003) 5089-5094
8. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 (1994) 1105-1110
9. Fonseca A.M., Porto G., Uchida K., and Arosa F.A. Red blood cells inhibit activation-induced cell death and oxidative stress in human peripheral blood T lymphocytes. Blood 97 (2001) 3152-3160
10. Fonseca A.M., Pereira C.F., Porto G., and Arosa F.A. Red blood cells promote survival and cell cycle progression of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds. Cell. Immunol. 224 (2003) 17-28
11. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., and Presky D.H. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16 (1998) 495-521
12. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., and Ferrara J.L.M. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
13. Kauffman C.L., Aria N., Toichi E., McCormick T.S., Cooper K.D., Gottlieb A.B., Everitt D.E., Frederick B., Zhu Y., Graham M.A., et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123 (2004) 1037-1044
14. Kharitonenkov A., Chen Z., Sures I., Wang H., Schilling J., and Ullrich A. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386 (1997) 181-186
15. Latour S., Tanaka H., Demeure C., Mateo V., Rubio M., Brown E.J., Maliszewski C., Lindberg F.P., Oldenborg A., Ullrich A., et al. Bidirectional negative regulation of human T and dendritic cells by CD47 and its cognate receptor signal-regulator protein-alpha: down-regulation of IL-12 responsiveness and inhibition of dendritic cell activation. J. Immunol. 167 (2001) 2547-2554
16. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., Sosman J.A., Dutcher J.P., Vogelzang N.J., and Ryan J.L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90 (1997) 2541-2548
17. Ma X., and Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 79 (2001) 55-92
18. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., Dolin B., Goodman N., Groden C., Hornung R.L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351 (2004) 2069-2079
19. Morita Y., Yamamura M., Nishida K., Harada S., Okamoto H., Inoue H., Ohmoto Y., Modlin R.L., and Makino H. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 41 (1998) 306-314
20. Murphy T.L., Cleveland M.G., Kulesza P., Magram J., and Murphy K.M. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol. Cell. Biol. 15 (1995) 5258-5267
21. Neznanov N., Neznanova L., Kondratov R.V., Burdelya L., Kandel E.S., O'Rourke D.M., Ullrich A., and Gudkov A.V. Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. J. Biol. Chem. 278 (2003) 3809-3815
22. O'Doherty U., Peng M., Gezelter S., Swiggard W.J., Betjes M., Bhardwaj N., and Steinman R.M. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 82 (1994) 487-493
23. Oldenborg P.A., Zheleznyak A., Fang Y.F., Lagenaur C.F., Gresham H.D., and Lindberg F.P. Role of CD47 as a marker of self on red blood cells. Science 288 (2000) 2051-2054
24. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
25. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., and Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 52 (2003) 133-144
26. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., and Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282 (1998) 480-483
27. +)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J. Exp. Med. 196 (2002) 517-527
28. Robertson M.J., Soiffer R.J., Wolf S.F., Manley T.J., Donahue C., Young D., Herrmann S.H., and Ritz J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175 (1992) 779-788
29. Schäkel K., Mayer E., Federle C., Schmitz M., Riethmuller G., and Rieber E.P. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 28 (1998) 4084-4093
30. Schäkel K., Kannagi R., Kniep B., Goto Y., Mitsuoka C., Zwirner J., Soruri A., von Kietzell M., and Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 17 (2002) 289-301
31. Schmitz M., Zhao S., Schäkel K., Bornhauser M., Ockert D., and Rieber E.P. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 100 (2002) 1502-1504
32. Schmitz M., Zhao S., Deuse Y., Schäkel K., Wehner R., Wohner H., Holig K., Wienforth F., Kiessling A., Bornhauser M., et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J. Immunol. 174 (2005) 4127-4134
33. Seiffert M., Cant C., Chen Z., Rappold I., Brugger W., Kanz L., Brown E.J., Ullrich A., and Buhring H.-J. Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94 (1999) 3633-3643
34. Smith R.E., Patel V., Seatter S.D., Deehan M.R., Brown M.H., Brooke G.P., Goodridge H.S., Howard C.J., Rigley K.P., Harnett W., and Harnett M.M. A novel MyD-1 (SIRP-1alpha) signaling pathway that inhibits LPS-induced TNFalpha production by monocytes. Blood 102 (2003) 2532-2540
35. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J., and The Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor {alpha} for Crohn's disease. N. Engl. J. Med. 337 (1997) 1029-1036
36. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3 (2003) 133-146
37. Weighardt H., Jusek G., Mages J., Lang R., Hoebe K., Beutler B., and Holzmann B. Identification of a TLR4- and TRIF-dependent activation program of dendritic cells. Eur. J. Immunol. 34 (2004) 558-564
38. Wu C.J., Chen Z., Ullrich A., Greene M.I., and O'Rourke D.M. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 19 (2000) 3999-4010
39. Youn H.S., Lee J.Y., Fitzgerald K.A., Young H.A., Akira S., and Hwang D.H. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 175 (2005) 3339-3346